Entyvio
Entyvio is a prescription medicine used in adults for the treatment of:
- moderately to severely active ulcerative colitis
- moderately to severely active Crohn’s disease
Entyvio (vedolizumab), an integrin receptor antagonist, is a humanized IgG1 monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin. Entyvio has an approximate molecular weight of 147 kilodaltons.
Entyvio Info
Entyvio can be administered by intravenous infusion.
The recommended dosage of ENTYVIO in adults with ulcerative colitis or Crohn’s disease is 300 mg administered by intravenous infusion at zero, two, and six weeks and then every eight weeks thereafter.
Entyvio Side Effects
The most common side effects include:
- common cold symptoms (runny or stuffy nose, sinus pain, sneezing, cough),
- headache,
- joint pain,
- nausea,
- fever,
- infections of the nose and throat,
- tiredness,
- fatigue,
- upper respiratory tract infection,
- bronchitis,
- flu symptoms,
- back pain,
- rash,
- itching,
- sinus infection,
- sore throat, and
- pain in your arms or legs
Patient Assistance Programs
There are several programs patients can sign up for that will assist in treatment costs:
Resources
To learn more about this treatment, browse the resources below.
Ready to get started?
Contact us to chat with one of our helpful scheduling specialists!